Hirata et al. also showed that melanoma-associated fibroblasts in the ECM could provide a “safe haven” for melanoma cells, increasing the ECM rigidity following BRAF inhibitor treatment and thus protecting melanoma cells from targeted therapy [26]. This evidence concerns the gene BRAF and melanoma.